Latest Bleeding Stories

A study of patients treated with the anticoagulant medication warfarin suggests that resuming warfarin therapy after an episode of gastrointestinal tract bleeding was associated with lower risk for thrombosis (blood clot) and death, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication. Gastrointestinal tract bleeding (GIB) affects about 4.5 percent of patients treated annually with warfarin. A history of major bleeding can be a predictor...

SARASOTA, Fla., Sept. 18, 2012 /PRNewswire/ -- WoundSeal, a topical powder that stops bleeding instantly for the more than 50 million seniors on blood thinners, is available for the first time over-the-counter. Created by seniors for seniors, WoundSeal was invented by accident when the product's innovator, Dr. James Patterson, was testing potassium iron oxyacid salt for water purification technology. Dr. Patterson cut his hand and noticed that when the powder mixed with his blood, it...

Parker Waichman LLP is alerting the public about a new review published in the Journal of the American Medical Association (JAMA) that highlights the risks of expedited approval for drugs like Pradaxa (dabigatran). Originally hailed as an innovative warfarin replacement, Pradaxa is part of a new generation of anticoagulants that has been associated with uncontrollable bleeding risks. New York, NY (PRWEB) September 06, 2012 Parker Waichman LLP, a national law firm dedicated to protecting...

RARITAN, N.J., Sept. 7, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that it has submitted the Complete Response to the U.S. Food and Drug Administration (FDA) for the use of XARELTO(®) (rivaroxaban) to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS). The response includes specific information requested by the FDA in their letter issued to Janssen on June 21, 2012. Janssen also has...

Some Smaller Clots May Not Require Potentially Risky Treatment ROSEMONT, Ill., Sept. 4, 2012 /PRNewswire-USNewswire/ -- Men and women who undergo joint replacement procedures, as well as those who have significant fractures, tend to be at an increased risk of developing pulmonary emboli (PE), blood clots that travel to the lungs where they may cause serious complications and even death. Patients are often aggressively treated with anticoagulants, or blood thinners, to help prevent...

Some smaller clots may not require potentially risky treatment Men and women who undergo joint replacement procedures, as well as those who have significant fractures, tend to be at an increased risk of developing pulmonary emboli (PE), blood clots that travel to the lungs where they may cause serious complications and even death. Patients are often aggressively treated with anticoagulants, or blood thinners, to help prevent the clots from forming, but a study published in the September...

Progress toward a new emergency treatment for internal bleeding ― counterpart to the tourniquets, pressure bandages and Quick Clot products that keep people from bleeding to death from external wounds ― was reported here today at the 244th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society. Erin Lavik, Sc.D., who described the advance toward developing synthetic platelets, said it is among the efforts underway world-wide to treat...

Parker Waichman LLP has filed a lawsuit on behalf of a man who experienced hemorrhaging, allegedly due to the use of Plavix (clopidogrel). The lawsuit alleges that Plavix caused the bleeding and claims that the Defendants failed to fully inform users about the risks of taking the blood-thinning medication. New York, NY (PRWEB) August 20, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit against...

WALLINGFORD, Conn., Aug. 13, 2012 /PRNewswire/ -- A new study has found the use of gauze that includes the hemostatic agent kaolin to be 100% effective in stopping traumatic bleeding by second application in a model of simulated hemorrhagic shock. In the study, treatment with QuikClot Combat Gauze®, a specially engineered surgical gauze impregnated with kaolin, successfully stopped bleeding in extreme physiologic conditions normally associated with a significant risk of fatality....

WAYNE, N.J., July 12, 2012 /PRNewswire/ -- Bayer HealthCare announced results from SPINART, a study designed to evaluate the effect of secondary prophylaxis with Kogenate® FS - antihemophilic factor (recombinant) on bleeding frequency and joint damage compared to on-demand treatment in adults and adolescents with severe hemophilia A. These data were presented as a late-breaker at the 50(th) annual World Federation of Hemophilia (WFH) World Congress, July 8-12, in Paris, France. In...